A quick look at recent stock market activity, including analyst ratings updates for Vera Therapeutics, RF Industries, and United Therapeutics, plus short interest fluctuations in MingZhu Logistics and XOMA Co. Read more...

This article summarizes recent analyst ratings for several NASDAQ-listed stocks, including Akero Therapeutics, Alumis, Amneal Pharmaceuticals, BRP Inc., Amplitude, and SoundHound AI. Read more...

This week's analyst activity includes price target adjustments for Portland General Electric, Neumora Therapeutics, Microchip Technology, ICON Public, and MongoDB. Read more...

Recent stock market activity includes changes in holdings for Wingstop, increased short interest in Alto Ingredients and Amalgamated Financial, and analyst upgrades for Okta and Roivant Sciences. Read more...

Asian shares show mixed performance amid Trump's tariffs, while some US companies see stock fluctuations after earnings reports. Direct mail marketing also remains relevant. Read more...

A mixed bag for investors: Axon Enterprise stock fell in February, while Cracker Barrel and Zscaler saw positive movement after earnings reports. Plus, analyst updates on ATSG, Humacyte, and Aptose Biosciences. Read more...

This week's market update covers analyst ratings for COMPASS Pathways and Qualys, EPS forecasts for Doman Building Materials, dollar fluctuations influenced by Trump, and a major fraud case. Read more...

Analysts issue earnings forecasts for SBC Medical, Nuvalent, and Intrusion, while OptimumBank prepares to announce quarterly results. Logitech announces a share buyback program. Read more...

A roundup of recent analyst ratings for various stocks, including Astronics, Lloyds Banking Group, Oklo, Amylyx Pharmaceuticals, NatWest Group, and GE Vernova, providing insights for investors. Read more...

A summary of recent business news, including an Italian tax investigation into Elon Musk and updates on several companies' stock ratings and earnings estimates. Read more...

Praxis faces a complex investment landscape. Despite a "Hold" rating and setbacks with Ulixacaltamide, the company presents a high-risk, high-reward opportunity in the epilepsy sector. Read more...

A look at Q4 2024 financial results and analyst reviews for Target, Fidelity Mid-Cap Stock Fund, Martinrea International, American Airlines, and TG Therapeutics. Read more...